An additional important objective of these safety studies was to assess the safety of initiating development of rHuIL-12 as a multilineage hematopoietic and immunotherapeutic agent in patients with cancer who are receiving aggressive chemotherapy, where single doses of IL-12 are planned to be used once per chemotherapy cycle. The gene discussed is SPRR2A; the disease is cancer.